62nd ASH Annual Meeting and Exposition: Integrating MRD into Clinical Trial Design and Clinical Practice

Scientific Workshops @ ASH

Moderator:

Disclosures:

Holstein: Celgene: Consultancy; GSK: Consultancy; Sorrento: Consultancy; Takeda: Consultancy; Adaptive Biotechnologies: Consultancy; Oncopeptides: Consultancy, Research Funding; Sanofi: Consultancy; Genentech: Consultancy.

MRD Practices Survey Data

Sarah A. Holstein, MD, PhD

University of Nebraska Medical Center, Omaha, NE

Regulatory Considerations Surrounding Novel Endpoints and Biomarker-Driven Clinical Trials in Myeloma

Nicole J. Gormley, MD

U.S. Food and Drug Administration, Bethesda, MD

EMA Perspective of Integrating MRD into Clinical Trial Design and Clinical Practice in Multiple Myeloma Therapy

Pierre Demolis, MD, PhD

European Medicines Agency, Paris, Finland

FORTE MRD Study Results

Francesca Gay, MD

Citta' della Salute e della Scienza di Torino, Turin, Italy

Panel Discussion & Live Q&A

See more of: Scientific Workshops @ ASH

<< Previous Session | Next Session >>